JR

Jiaqi Ren, MS

VP of Finance

Accutar Biotechnology

Therapeutic Areas

Accutar Biotechnology Pipeline

DrugIndicationPhase
AC699ER+/HER2-, ESR1-mutated advanced or metastatic breast cancerPhase 1